Major Treatment Decisions for Patients with Acute Myeloid Leukemia (AML)
This is a recording of a webinar aired on Monday, October 17, 2022 Speaker: Dr. Fred Appelbaum, Executive Vice President of Fred Hutch Cancer Center and Associate Director for Clinical Research at the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium.
▶︎
Maintenance Therapy after Transplant: Acute Myeloid Leukemia (AML)
▶︎
Acute Myeloid Leukemia: What to Know, What to Do
▶︎
Acute Myeloid Leukemia: Treatment Advances
▶︎
CMML - Diagnosis & Treatment :a presentation by consultant haematologist Dr. Daniel Wiseman
▶︎
Long-Term Effects of a Transplant Using Your Own Stem Cells (autologous transplant)
▶︎
Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies
▶︎
Lp(a), ApoB, and the New ACC Dyslipidemia Guidelines
▶︎
The Mind After Transplant and CAR T
▶︎
AML diagnosis and treatment 2022
▶︎
Leukemias: Pathology review
▶︎
AI Is Creating A Rare Opportunity For Investors. How Jim Roppel Is Playing It. | Investing With IBD
▶︎
Chronic Myeloid Leukemia Explained
▶︎
Managing Life With AML | What You Should Know About Care and Treatment
▶︎
Treatment Assessments for AML Care | Dr. James Dugan
▶︎
CLL Treatment EXPLAINED!
▶︎
Treating Acute Myeloid Leukemia (AML) in Older Adults
▶︎
"I Had Every Symptom of Leukemia & I Explained Them All Away" | Michele's CML Story
▶︎
Measurable Residual Disease (MRD) in AML and ALL
▶︎
Acute Myelogenous Leukemia AML: Transplant or Not?
▶︎